IgA Nephropathy After SARS-CoV-2 Vaccination

Overview

Journal Kidney Med

Specialty Nephrology

Date 2021 Jul 19

PMID 34278290

Citations 35

Authors

Matthew Abramson

Samuel Mon-Wei Yu

Kirk N Campbell

Miriam Chung

Fadi Salem

Affiliations

Soon will be listed here.

Abstract

Here we present the first case of newly diagnosed IgA nephropathy (IgAN) after a SARS-CoV-2 vaccination. A 30-year-old man with no known past medical history presented with gross hematuria and subnephrotic proteinuria 24 hours after the second dose of the mRNA-1273 SARS-CoV-2 vaccine. A kidney biopsy showed IgAN. He was started on an angiotensin receptor blocker, resulting in proteinuria reduction. Similar to natural infection of SARS-CoV-2, persons who receive 2 mRNA-based vaccines demonstrate robust antibodies against the receptor-binding domain (RBD) of the S1 protein. Given the uniqueness of glycosylation of RBD and potent stimulation of immune response from mRNA-based vaccine compared to other vaccines, we hypothesize that our patient developed de novo antibodies, leading to IgA-containing immune-complex deposits. This case highlights the urgency of understanding the immunological responses to novel mRNA-based SARS-CoV-2 vaccines in more diverse populations. Despite the lack of clear causality, nephrologists should be alerted if any new-onset hematuria or proteinuria is observed.

Citing Articles

De Novo Biopsy-Proven Glomerular Disease Following COVID-19 Vaccination.

Chen C, Chiu Y, Chen B, Wu M, Tsai S J Clin Med. 2024; 13(15).

PMID: 39124761 PMC: 11313347. DOI: 10.3390/jcm13154494.

Recovery from antibody-mediated biliary ductopenia and multiorgan inflammation after COVID-19 vaccination.

Chang A, Jeng Y, Ho C, Lee P NPJ Vaccines. 2024; 9(1):75.

PMID: 38589436 PMC: 11001909. DOI: 10.1038/s41541-024-00861-9.

Successful treatment of new-onset diabetes mellitus and IgA nephropathy after COVID-19 vaccination: a case report.

Qu L, Zhang A, Xu G, Wang X, Lou H, Lou J Am J Transl Res. 2023; 15(11):6626-6631.

PMID: 38074820 PMC: 10703642.

Viral Glomerulopathy.

Deoliveira M, Sikri H, Yu S, He J Glomerular Dis. 2023; 3(1):148-154.

PMID: 37901695 PMC: 10601964. DOI: 10.1159/000531434.

Renal outcomes in IgA nephropathy following inactivated SARS-CoV-2 vaccination.

Sun K, Shang D, Hao C, Lai L Clin Exp Nephrol. 2023; 28(1):23-30.

PMID: 37713044 DOI: 10.1007/s10157-023-02398-y.

References

Perrin P, Bassand X, Benotmane I, Bouvier N . Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy. Kidney Int. 2021; 100(2):466-468. PMC: 8166778. DOI: 10.1016/j.kint.2021.05.022. View

Premkumar L, Segovia-Chumbez B, Jadi R, Martinez D, Raut R, Markmann A . The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020; 5(48). PMC: 7292505. DOI: 10.1126/sciimmunol.abc8413. View

Fischer A, Moller B, Krag S, Jespersen B . Influenza virus vaccination and kidney graft rejection: causality or coincidence. Clin Kidney J. 2015; 8(3):325-8. PMC: 4440474. DOI: 10.1093/ckj/sfv027. View

Lai K . Pathogenesis of IgA nephropathy. Nat Rev Nephrol. 2012; 8(5):275-83. DOI: 10.1038/nrneph.2012.58. View

Gul Rahim S, Lin J, Wang J . A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. Kidney Int. 2021; 100(1):238. PMC: 8079938. DOI: 10.1016/j.kint.2021.04.024. View

Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L . IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2020; 13(577). PMC: 7857408. DOI: 10.1126/scitranslmed.abd2223. View

Barbour S, Coppo R, Zhang H, Liu Z, Suzuki Y, Matsuzaki K . Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Intern Med. 2019; 179(7):942-952. PMC: 6583088. DOI: 10.1001/jamainternmed.2019.0600. View

Schena F, Nistor I . Epidemiology of IgA Nephropathy: A Global Perspective. Semin Nephrol. 2018; 38(5):435-442. DOI: 10.1016/j.semnephrol.2018.05.013. View

Patel C, Shah H . Vaccine-associated kidney diseases: A narrative review of the literature. Saudi J Kidney Dis Transpl. 2019; 30(5):1002-1009. DOI: 10.4103/1319-2442.270254. View

10.

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

11.

Trimarchi H, Barratt J, Cattran D, Cook H, Coppo R, Haas M . Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017; 91(5):1014-1021. DOI: 10.1016/j.kint.2017.02.003. View

12.

Hassan A, Kafai N, Dmitriev I, Fox J, Smith B, Harvey I . A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. Cell. 2020; 183(1):169-184.e13. PMC: 7437481. DOI: 10.1016/j.cell.2020.08.026. View

13.

Wisnewski A, Campillo Luna J, Redlich C . Human IgG and IgA responses to COVID-19 mRNA vaccines. PLoS One. 2021; 16(6):e0249499. PMC: 8208542. DOI: 10.1371/journal.pone.0249499. View

14.

McNally A, McGregor D, Searle M, Irvine J, Cross N . Henoch-Schönlein purpura in a renal transplant recipient with prior IgA nephropathy following influenza vaccination. Clin Kidney J. 2015; 6(3):313-5. PMC: 4400476. DOI: 10.1093/ckj/sft029. View

15.

Stamatatos L, Czartoski J, Wan Y, Homad L, Rubin V, Glantz H . mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021; . PMC: 8139425. DOI: 10.1126/science.abg9175. View

16.

van den Wall Bake A, Beyer W, Hermans J, Daha M, Masurel N, van Es L . Humoral immune response to influenza vaccination in patients with primary immunoglobulin A nephropathy. An analysis of isotype distribution and size of the influenza-specific antibodies. J Clin Invest. 1989; 84(4):1070-5. PMC: 329762. DOI: 10.1172/JCI114269. View

17.

Fernandez A . Glycosylation of SARS-CoV-2 Steers Evolutionary Outcomes in the Postvaccination Phase. ACS Pharmacol Transl Sci. 2021; 4(1):410-412. PMC: 7887837. DOI: 10.1021/acsptsci.1c00015. View

18.

Butler D, Imberti L, Quaresima V, Fiorini C, Gildersleeve J . Abnormal antibodies to self-carbohydrates in SARS-CoV-2-infected patients. PNAS Nexus. 2022; 1(3):pgac062. PMC: 9291223. DOI: 10.1093/pnasnexus/pgac062. View

19.

Novak J, Julian B, Tomana M, Mestecky J . IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol. 2008; 28(1):78-87. PMC: 2241661. DOI: 10.1016/j.semnephrol.2007.10.009. View

20.

HIKI Y, Odani H, Takahashi M, Yasuda Y, Nishimoto A, Iwase H . Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int. 2001; 59(3):1077-85. DOI: 10.1046/j.1523-1755.2001.0590031077.x. View